Viking Therapeutics Emerges as Prime Acquisition Target in Weight-Loss Drug Race

FDA approval of Eli Lilly's oral GLP-1 pill fuels takeover interest in Viking Therapeutics, whose Phase 3 drug VK2735 targets a $35B+ obesity market.

The recent FDA approval of Eli Lilly's oral GLP-1 pill, Foundayo, has reshuffled the competitive landscape for weight-loss medications, casting a bright spotlight on Viking Therapeutics. Market analysts now identify the company as one of the most compelling acquisition prospects within the sector.

A Strategic Asset in a Multi-Billion Dollar Market

Institutional projections estimate the long-term market for oral weight-management drugs could surpass $35 billion. This immense potential is drawing significant attention to Viking's lead drug candidate, VK2735. The treatment is a dual agonist targeting two distinct receptors and is currently undergoing a Phase 3 trial involving 1,000 patients. The company reached a critical milestone on March 26, announcing the completion of patient enrollment for its VANQUISH-2 study, marking a major step toward potential regulatory submission.

The approval of Eli Lilly's Foundayo acts as a dual-edged catalyst for Viking. While it introduces a new competitor, it also validates the strategic importance and commercial viability of the entire GLP-1 drug class. For any major pharmaceutical firm not already entrenched in this market, the risk of being left behind is substantial, a dynamic that is likely fueling acquisition interest in companies like Viking Therapeutics.

Market Speculation and Technical Momentum

Trading activity and public discussion have amplified the acquisition narrative. On April 2, during a CNBC "Fast Money" segment, traders openly debated which biotechnology firms might be the next takeover targets, with Viking Therapeutics frequently cited as a top contender. Following this broadcast, the company's shares climbed more than 2% in after-hours trading. This move came after a regular session where the stock was already among the most actively traded biotech equities.

From a technical analysis perspective, the equity has demonstrated notable strength. On April 1, it posted a gain of 7.35%, supported by a bullish crossover signal and an elevated Relative Strength Index reading. Over the preceding twelve-month period, the stock has advanced approximately 38%.

The Path Forward

The forthcoming data readouts from the VANQUISH-2 study will be pivotal. They will provide crucial evidence on VK2735's efficacy and safety profile, determining how close Viking Therapeutics is to bringing a competitive product to a rapidly expanding market. For larger pharmaceutical companies, the candidate represents significant value both as a potential standalone blockbuster and as a key asset justifying a multi-billion dollar acquisition. As the race in the obesity treatment space intensifies, Viking finds itself squarely in the crosshairs of industry giants seeking to bolster their portfolios.